ALX Oncology Holdings Inc. Common Stock (ALXO)

Price$1.80

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)23.78%

Price vs S&P 500 (4W)7.45%

VGM Score56.60

Market Capitalization$255.67M

All Metrics

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)1.67x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.58

Price vs S&P 500 (YTD)57.21%

Gross Margin (TTM)9.02%

Net Profit Margin (TTM)-753.55%

EPS (TTM)$-1.49

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$-1.49

EPS (Annual)$-2.60

ROI (Annual)-106.30%

Gross Margin (Annual)9.32%

Cash / Share (Quarterly)$1.04

ROA (Last FY)-91.22%

EBITD / Share (TTM)$-1.36

ROE (5Y Avg)-56.73%

Operating Margin (TTM)-731.97%

Cash Flow / Share (Annual)$-2.31

P/B Ratio1.69x

P/B Ratio (Quarterly)1.78x

Net Income / Employee (Annual)$-3,139,500

Net Interest Coverage (TTM)-8347.00x

ROA (TTM)-85.57%

EPS Incl Extra (Annual)$-2.60

Current Ratio (Annual)7.05x

Quick Ratio (Quarterly)6.99x

3-Month Avg Trading Volume0.93M

52-Week Price Return306.68%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.10

P/S Ratio (Annual)216.67x

Asset Turnover (Annual)0.00x

52-Week High$2.66

EPS Excl Extra (Annual)$-2.60

CapEx CAGR (5Y)47.86%

26-Week Price Return39.71%

Quick Ratio (Annual)6.78x

13-Week Price Return-19.15%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)7.21x

Enterprise Value$233.22M

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-3855.93%

Cash / Share (Annual)$2.42

3-Month Return Std Dev73.32%

Net Income / Employee (TTM)$-2,066,700

ROE (Last FY)-118.42%

Net Interest Coverage (Annual)-54.49x

EPS Basic Excl Extra (Annual)$-2.60

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-1.49

ROI (TTM)-107.13%

P/S Ratio (TTM)69.86x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.45

Price vs S&P 500 (52W)278.47%

Year-to-Date Return68.14%

5-Day Price Return-4.04%

EPS Normalized (Annual)$-2.60

ROA (5Y Avg)-46.04%

Net Profit Margin (Annual)-3876.27%

Month-to-Date Return11.76%

Cash Flow / Share (TTM)$-3.54

EBITD / Share (Annual)$-2.71

Operating Margin (Annual)-3752.54%

LT Debt / Equity (Annual)0.05x

ROI (5Y Avg)-52.96%

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)2.61x

P/B Ratio (Annual)0.77x

Pretax Margin (TTM)-753.01%

Book Value / Share (Annual)$2.15

Price vs S&P 500 (13W)-28.89%

Beta0.46x

Revenue / Share (TTM)$0.00

ROE (TTM)-124.06%

52-Week Low$0.40

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.15est. -0.20

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.09

4.08

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALXOALX Oncology Holdings Inc. Common Stock	—	—	C	$1.80
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

ALX Oncology is a clinical-stage immuno-oncology company developing CD47-blocking therapies to enhance the immune system's ability to recognize and eliminate cancer cells. The company's lead program, evorpacept, is in phase 1 and 2 clinical trials and targets the CD47 "don't eat me" signal that allows cancer cells to evade immune detection. ALX's approach leverages protein engineering expertise to achieve high CD47 affinity while avoiding the hematologic toxicities that limit other CD47-blocking strategies.